The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival

Autor: Ahmet Bilici, A. Develi, Fugen Aker Vardar, B. B. Oven Ustaalioglu, Burcak Erkol, Ozlem Balvan, Mehmet Aliustaoglu

WOS: 000363023000009 PubMed ID: 26081286 In the literature, small number of study has addressed time of recurrence in breast cancer. We analyzed clinicopathological factors predicting early or late recurrence in breast cancer patients and also progno

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44efd2cf016e21514e701f35053f6f27
https://hdl.handle.net/20.500.12511/2220

A retrospective analysis of women's chances to become pregnant after completion of chemotherapy: a single center experience

Autor: B B, Oven Ustaalioglu, A, Bilici, U, Kefeli, M, Seker, T, Salepci, O, Unal, M, Gumus

Publikováno v: Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 16(2)

With the improvement in anticancer therapies, the survival of women with malignancies has increased and infertility may affect the quality of life of premenopausal women, who experience temporary or permanent amenorrhea due to chemotherapy. The aim o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6482d690c43736917f48f752ca50b5e1
https://pubmed.ncbi.nlm.nih.gov/21766510

Comparison of Second Line Treatment Outcomes Between Sensitive and Refractory Small Cell Lung Cancer Patients: a Retrospective Analysis

Autor: Ozlem Balvan, B. B. Oven Ustaalioglu, Mahmut Gumus, E. Sari, Umut Kefeli, Nurgul Yasar, Serdar Turhal, Taner Korkmaz, Selcuk Seber, Mustafa Canhoroz

Publikováno v: Annals of Oncology. 23:ix497-ix498

Introduction Small cell lung cancer (SCLC) has a high relaps rate despite being very chemosensitive. The prognosis of these patients is generally poor. The efficasy of second line treatment is dismal when compared to other chemosensitive tumors such

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9e90e8b08c146136b7c6f9de9137e17
https://doi.org/10.1016/s0923-7534(20)34086-2

Phase II Study of Amrubicin in Patients with Refractory or Resistant Relapsed Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG0901)

Autor: Masaharu Nishimura, G. Galffy, Q. Cheng, N. Stjepanovic, B. B. Oven Ustaalioglu, M.A. Damiano, G. Sajjady, J. Cai, B. Wallin, J. Dimitroulis, M. Reck, Judit Kocsis, B. Dome, S. Mellor, Y. Okuma, G. Le Teuff, N. Muzzafar, S. Yang, T. Tamura, S.A. Kazmi, G. Fust, H. Isobe, L. Graf, R. Eckert, D. Easty, S. Ahn, M. Chacon, D.A. Fennell, H. Daga, D. Pérez-Callejo, Raffaele Califano, Y. Ohe, Angela C. Casbard, Pablo Martinez, Y. Hosomi, H. Murakami, M. Salcedo, Y-C. Kim, Mustafa Canhoroz, Y. Fujita, A. Verlicchi, I. Oh, M.A. Burgio, S. Imtiaz, C. Kurkjian, M.A. Montero, A. Rosales, D. Pérez Callejo, C. Park, P. Ibeas, Susana Cedres, S. Heavey, Thierry Jahan, X. Wang, K. Kim, G. Stathopoulos, W. Sterlacci, M. Palka, N.B. Leighl, Satoshi Oizumi, Benjamin Besse, E. Almagro Casado, G. Gavelli, M. Yomoda, K. Takamura, C. Maximiano, J.W. Heyburn, Selcuk Seber, C. Lou, Wolfgang Hilbe, L. Tamasi, W. Mao, L. Ampollini, A. Santo, Jason F. Lester, D. Simos, H. Yang, J-C. Soria, H. Jamnig, S. Kuom, H. Ban, S. Sanna, Gareth Griffiths, Y. Ichinose, K. Na, D. Tsavdaridis, Taner Korkmaz, Z. Segota, R. Buosi, Lisette Sheena Nixon, G. Pall, K.A. Gately, M. Leschke, C. Martin, T. Schmid, P. Godwin, Hirotoshi Dosaka-Akita, M.E. Guiterrez, L. Lei, J. Edwards, C. Ho, Z. Prohaszka, David Planchard, H. Lu, Athanassios Argiris, J. Qin, M. Nevinny, Yvonne Summers, Y. Takagi, M. Endo, K.J. O'Byrne, T. Okamura, Z. Orosz, B. Cantos, A. Martinez, A. Falco, M. Mezzetti, E. Flechter, H. Watanabe, Umut Kefeli, G. Zangerl, M.S. Liew, R. Hassan, Serdar Turhal, A.C. Mita, I.A. Muazzam, Z. Bartfai, D. Nonaka, O.S. Breathnach, M. Monti, Harvey I. Pass, C. Poleri, O. Balvan, S. White, L. Mutti, J. Margery, W. Kim, Hedy L. Kindler, Hajime Asahina, M. Rosenberg, Mahmut Gumus, A. Pircher, A. López-González, N. Siddiqui, D. Torrejon Castro, V. Vilchez, R. Chacon, Dean A. Fennell, K. Umezawa, A. Szilagyi, T. Kojima, R. Mastico, Enriqueta Felip, Y. Zhang, P. Wheatley-Price, R. Guild, Rastilav Bahleda, D. Traphalis, M. Sergi, O. Ben Itzhak, T. Shibata, A.K. Patané, K. Das, S. Kumar, O. Vaisman, J. Stathopoulos, N. Yasar, W.M. Grogan, A. Soltermann, Steven G. Gray, H. Kang, J. Clince, M. Faehling, C.L. Hann, M. Barr, Lyudmila Bazhenova, B.G. Doger de Speville, A. Ruiz-Valdepeñas, Anne-Marie Baird, C. Kosmas, Y. Nakahara, T. Harada, J.D. Maltzman, M. Provencio Pulla, J. Parno, N. Yamamoto, M. Wollner, Antoine Hollebecque, David R. Spigel, Willi Oberaigner, Y. Kawai, M. Shibuya, E. Sari, E. Almagro-Casado, M. Mendez Garcia, N.J. Coleman, J. Raphael, Johanna C. Bendell, M. Fiegl, I. Opitz, G. Diaz, E. Jennions, Christophe Massard, G. Genestreti, M. Iguchi, P. Fatato

Publikováno v: Annals of Oncology. 23:ix492

Background Standard therapy for refractory or resistant relapsed small-cell lung cancer (SCLC) has not yet been established. We conducted an open-label, multicenter, non-randomized phase II study to confirm the efficacy and safety of amrubicin, a top

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3285e282bfecba0a422afa8f2b2c30d7
https://doi.org/10.1093/annonc/mds415